The AI Innovation Lab in London and Mainz, Germany will be formed to apply the latest artificial intelligence and machine-learning technologies to develop novel immunotherapies for a range of cancers and infectious diseases, including COVID-19. The collaboration will combine InstaDeep's advanced capabilities in artificial intelligence, machine learning, and digitalization with BioNTech's expertise in precision immunotherapies.

One of the key research focus areas of the lab will be development of next generation vaccines and biopharmaceuticals for the treatment of cancer and prevention and treatment of infectious diseases. This includes applying InstaDeep's DeepChain protein design platform to engineer new messenger RNA sequences for protein targets. The companies plan to generate insights from proprietary patient meta datasets and optimize manufacturing and supply chain processes by utilizing AI and machine-learning applications.